Below the resistance zone that is currently being tested, the potential for new gains appears limited for shares in Pfizer Inc.. The stock's technical chart pattern suggests however that the level will be broken. Investors have an opportunity to buy the stock and target the $ 44.7.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
The company is in debt and has limited leeway for investment
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The company's enterprise value to sales, at 5.06 times its current sales, is high.
ę MarketScreener.com 2020
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.